Seer, Inc. SEC Filings

Denali Therapeutics Inc. (DNLI) filed a Form 144 indicating a planned insider sale of 495,282 common shares. The shares have an aggregate market value of approximately $7.10 million based on the broker’s data supplied in the filing. The proposed transaction will be executed through Jefferies LLC on or after 9 July 2025 on the NASDAQ exchange.

The shares were originally acquired on 21 August 2015 via a stock-option exercise. No sales by the same account holder were reported in the prior three-month period, and no non-cash consideration or special payment terms were disclosed. With 145 million shares outstanding, the planned sale represents roughly 0.34 % of total shares, suggesting limited dilution or float impact. No remarks, Rule 10b5-1 plan dates, or material adverse information were provided, and the filer attested to compliance with Rule 144 requirements.

Sezzle Inc. (SEZL) – Form 4 insider transaction

Chief Financial Officer Karen Hartje sold an aggregate 5,484 shares of Sezzle common stock on 7 July 2025 under a pre-arranged Rule 10b5-1 trading plan adopted 20 Sep 2024. Sales were executed in five tranches at weighted-average prices ranging from $166.86 to $179.00 per share. Following the transactions, Hartje directly owns 126,846 shares, down roughly 4 % from the prior 132,330 shares.

The filing reports only non-derivative sales; no option exercises or other derivative activity occurred. Because the plan was disclosed and Hartje retains a sizeable equity stake, the move appears to be routine portfolio diversification rather than a strategic shift, but it nevertheless represents modest insider selling pressure.

Viasat Inc. (VSAT) – Form 4 insider filing

On 07 July 2025, Girish Chandran, President, Global Space Networks, reported the vesting of 8,334 restricted stock units (transaction code “M”). The RSUs converted 1-for-1 into common shares at no cost. To satisfy payroll-tax obligations, 4,488 shares were automatically surrendered to the company at $15.93 per share (code “F”), leaving a net increase of 3,846 shares in Chandran’s direct holdings.

Post-transaction ownership: 46,255 direct shares, 5,644 shares in the officer’s 401(k) and 176 in a spouse 401(k), plus 16,666 unvested RSUs remaining from the original 25,000-unit grant dated 06 Jun 2024. The next two RSU tranches are scheduled to vest on the second and third anniversaries of that grant, subject to continued employment.

No open-market purchase or sale occurred; the filing reflects routine equity-compensation vesting and tax withholding. Therefore, the signal for investors is considered neutral with limited immediate impact on Viasat’s valuation.

Rubric Capital Management LP, an investment adviser headquartered in New York, and its managing member David Rosen jointly filed Amendment No. 2 to Schedule 13G on 07 July 2025 regarding their holdings in Ovid Therapeutics Inc. (OVID).

• Beneficial ownership: 478,533 common shares.
• Ownership percentage: 0.67 % of the 71,109,514 shares outstanding as of 19 May 2025 (per the issuer’s latest proxy).
• Voting & disposition rights: 0 shares sole voting/dispositive power; 478,533 shares shared voting and shared dispositive power.
• Reporting persons: Rubric Capital (investment adviser) and David Rosen (individual, control person).
• Filing trigger date: 30 June 2025; the position is now below the 5 % threshold, leading to a “Ownership of 5 percent or Less” disclosure.
• Certification: Securities held in the ordinary course and not for the purpose of influencing control.

The filing is informational, confirming a modest (<1 %) stake by Rubric Capital without indicating any intent to alter the company’s control or strategy.

Seer, Inc. (NASDAQ: SEER) has filed an 8-K disclosing two key matters arising from its 2025 Annual Meeting held on July 7, 2025.

Item 3.01 – Nasdaq Audit-Committee Non-Compliance: The company informed Nasdaq that, following the meeting, its Audit Committee will drop below the minimum three-member requirement and will lack the mandated “financially sophisticated” director, putting Seer out of compliance with Listing Rule 5605(c)(2)(A). Seer intends to use the cure period allowed under Rule 5605(c)(4)(B) and is actively reviewing Board and committee composition to regain compliance before the cure window lapses.

Item 5.07 – Shareholder Voting Results:

• Quorum: 85,881,548 votes represented (≈90.16% of eligible votes).
• Director elections: All six nominees—Omid Farokhzad, Meeta Gulyani, Terrance McGuire, Robert Langer, Dipchand Nishar and Nicolas Roelofs—were elected. Support ranged from 86.4% (McGuire) to 99.1% (Gulyani) of votes cast.
• Auditor ratification: Deloitte & Touche LLP was re-appointed with 85,859,701 “FOR”, only 4,444 “AGAINST” and 17,403 abstentions.

No earnings data, transactions or operational updates were provided. The primary investor takeaway is the potential listing-status risk if the Audit Committee deficiency is not remedied within Nasdaq’s cure period.